Home Cart Sign in  
Chemical Structure| 1611493-60-7 Chemical Structure| 1611493-60-7

Structure of Bictegravir
CAS No.: 1611493-60-7

Chemical Structure| 1611493-60-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Bictegravir is a potent, unboosted, once-Daily HIV-1 Integrase Strand Transfer inhibitor (INSTI) (IC50 - 1.6 nM) with improved pharmacokinetics and in vitro resistance profile.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Tiede, Erin R ;

Abstract: The analysis of small molecules is an integral part of many industries and disciplines. The techniques used for small molecule analysis vary greatly depending on the purpose of analysis and the matrix of the samples being analyzed. This dissertation focuses on the combined use of liquid chromatography (LC) for the separation of complex samples and mass spectrometry (MS) for the detection of a variety of classes of compounds. Chapter 2 describes the development of a targeted LC-MS method for use in the validation of a putative biomarker for autism spectrum disorders (ASD). Previous work has indicated a depletion of stercobilin in ASD models, however the complex matrix of biological samples can lead to issues quantitating this sometimes low abundance molecule. This reversed-phase LC method was developed specifically to separate stercobilin from the species most similar to it in structure, urobilin and half-stercobilin, for improved quantitation. The method was then applied to the quantitation of stercobilin in fecal samples from a Fragile X syndrome murine model using an 18O-labeled internal standard. Chapter 3 describes the untargeted analysis of aqueous cinnamon extract, which has previously been indicated to have activity. The matrix of plant extracts is known to be extremely complex, so a reversed-phase LC-MS method was developed to separate the components as much as possible for identification. Fractions were collected from the separation to aid in narrowing down the potential species inducing activity. High-resolution MS/MS filtered through Compound Discover was used for the tentative identification of compounds in the full extract as well as the fraction that indicated the most potential for activity. Chapter 4 focuses on the untargeted analysis of bacterial spent media for the determination of a small molecule or molecules that can induce the growth of Porphyromonas gingivalis from low cell density. Both reversed-phase and HILIC separations were developed to cover the wide range of polarities that the species in this matrix contain. To help narrow down the potential active species, these methods were applied to further fractionate spent media fractions that induced Porphyromonas gingivalis growth activity from low cell density. These methods coupled to high-resolution MS/MS were also used in conjunction with Compound Discoverer for tentative identification of the matrix components. Chapter 5 continues work on bacterial spent media for the targeted, quantitative analysis of small organic acids. An LC-MS method was developed for the separation and quantitation of acetic, butyric, fumaric, lactic, propionic, succinic, and valeric acids. A variety of column chemistries were tested, with a HILIC column providing the best separation. This method was applied to wild type and lactate dehydrogenase mutant bacterial spent media to aid in determining the cause of a decreased media pH. Finally, Chapter 6 describes the use of a compendial testing method developed by the Clinical Pharmacology Quality Assurance (CPQA) program for examining the fitness of standard reference materials for proficiency testing. The standard reference materials were compared to certified reference materials and their certificates of analysis in both purity and identity tests. Purity was determined using a combination of high-performance liquid chromatography (HPLC) and thermogravimetric analysis (TGA). Identity confirmation was performed using both high-resolution MS and nuclear magnetic resonance (NMR) spectroscopy.

Purchased from AmBeed: ;

Alternative Products

Product Details of Bictegravir

CAS No. :1611493-60-7
Formula : C21H18F3N3O5
M.W : 449.38
SMILES Code : O=C(C1=CN(C2=C(O)C1=O)C[C@@]3([H])O[C@](C4)([H])CC[C@]4([H])N3C2=O)NCC5=C(F)C=C(F)C=C5F
MDL No. :MFCD31536971
InChI Key :SOLUWJRYJLAZCX-LYOVBCGYSA-N
Pubchem ID :90311989

Safety of Bictegravir

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02400307 HIV PHASE1 COMPLETED 2015-07-13 Avail Clinical Research, DeLan... More >>d, Florida, 32720, United States|Clinical Pharmacology of Miami, Inc., Miami, Florida, 33014-3616, United States|Orlando Clinical Research Center, Orlando, Florida, 32809, United States|Prism Clinical Research, Saint Paul, Minnesota, 55114, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, 37920, United States|Auckland Clinical Studies Limited, Grafton, Auckland, 1010, New Zealand|Christchurch Clinical Studies Trust, Christchurch, 8011, New Zealand Less <<
NCT06629480 Antiretroviral Treatment|HIV I... More >>nfection|Metabolic Cardiovascular Syndrome Less << COMPLETED 2024-02-28 Hospital de Infectología, "... More >>;La Raza" National Medical Center, Mexico City, 02990, Mexico Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.23mL

0.45mL

0.22mL

11.13mL

2.23mL

1.11mL

22.25mL

4.45mL

2.23mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories